Dysregulated BH4 metabolism facilitates immunosuppression in pancreatic cancer
Cell Metab. 2024 May 7;36(5):886-888. doi: 10.1016/j.cmet.2024.04.009.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive, malignant, and lethal cancers, displaying strong resistance to immunotherapy. In this issue of Cell Metabolism, a study by Liu et al. identifies tetrahydrobiopterin metabolic dysregulation as a key driver for the immunosuppressive PDAC environment in mouse and human.PMID:38718754 | DOI:10.1016/j.cmet.2024.04.009
Source: Cell Metabolism - Category: Cytology Authors: Shane J F Cronin Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cytology | Environmental Health | Immunotherapy | Pancreas | Pancreatic Cancer | Study